期刊
CLINICAL GENITOURINARY CANCER
卷 10, 期 4, 页码 225-231出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clgc.2012.08.002
关键词
Biologic markers; Enzyme inhibitors; Hypothyroidism; Kidney neoplasms; Protein kinase inhibitors; Sorafenib; Sunitinib
资金
- Paul Calabresi K12 clinical scholar grant [K12CA086913]
- National Institutes of Health
- Pfizer
- Bayer
Sorafenib and sunitinib cause hypothyroidism in a subset of patients. This retrospective study examined the incidence of hypothyroidism and its relationship to progression-free survival in renal cell carcinoma. We found that hypothyroidism occurs more frequently in patients treated with sunitinib and correlates with a longer progression-free survival, which could be useful as a biomarker for response to therapy. Introduction: Sunitinib and sorafenib are tyrosine kinase inhibitors used in metastatic renal cell carcinoma and are known to cause hypothyroidism in a subset of patients. The goal of this study was to better characterize the development of hypothyroidism in patients and to examine its relationship to progression-free survival. Patients and Methods: A retrospective chart review was performed on patients treated with sunitinib or sorafenib from January 1, 2005, to January 1, 2011. Data pertaining to the treatment course and development of hypothyroidism were extracted. Patients with hypothyroidism at the beginning of treatment were analyzed separately. Results: A total of 73 treatment periods had sufficient data to analyze. Among patients with normal baseline thyroid function, 15 (44%) of 34 patients treated with sunitinib and 6 (27%) of 22 patients treated with sorafenib developed hypothyroidism. The hazard ratio for the development of hypothyroidism with sorafenib vs. sunitinib treatment was significant, at 0.38 (95% CI, 0.14-0.97). There was a statistically significant difference in the progression-free survival between patients who developed hypothyroidism while receiving treatment compared with those who did not, 18.2 vs. 10.1 months (P = .01). Conclusions: This study demonstrated a significant difference in the incidence of hypothyroidism during treatment with sunitinib and sorafenib, with a higher incidence of hypothyroidism in patients treated with sunitinib. The development of hypothyroidism was associated with a longer progression-free survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据